The use of dendritic cells in cancer immunotherapy

A novel approach to vaccination against cancer is to exploit dendritic cells (DCs) as ‘nature’s adjuvants’ and actively immunize cancer patients with a sample of their own DCs primed with tumor antigens. DC vaccination is, however, still at an early stage, slowed in part by the need to carry out res...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in immunology 2003-04, Vol.15 (2), p.138-147
Main Authors: Schuler, Gerold, Schuler-Thurner, Beatrice, Steinman, Ralph M
Format: Article
Language:English
Subjects:
Animals
Cancer Vaccines - therapeutic use
Dendritic Cells - immunology
Humans
Immunotherapy, Adoptive
Monitoring, Immunologic
Neoplasms - immunology
Neoplasms - therapy
T-Lymphocytes, Cytotoxic - immunology
Vaccination
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A novel approach to vaccination against cancer is to exploit dendritic cells (DCs) as ‘nature’s adjuvants’ and actively immunize cancer patients with a sample of their own DCs primed with tumor antigens. DC vaccination is, however, still at an early stage, slowed in part by the need to carry out research in humans. Nevertheless, valuable proofs of concept have been obtained with respect to the capacity of DCs to expand cancer-directed immune responses. The methods for preparing DCs are being improved continuously, and there are many opportunities to improve efficacy at the level of DC biology. An increased number of Phase I, II and III studies will drive this new area of human research.
ISSN:0952-7915
1879-0372
DOI:10.1016/S0952-7915(03)00015-3